The Beijing News (Reporter Wang Kara) On June 10th, Pharm Exec published the TOP50 list of global pharmaceutical companies in 2023. Pfizer topped the list with US$ 913, and four companies in China were listed, namely China Biopharmaceutical, Shanghai Pharmaceutical, Hengrui Pharma and Unacon.
TOP50 list of global pharmaceutical companies in 2023 is ranked mainly according to the sales revenue of prescription drugs in fiscal year 2022 of each pharmaceutical company. Focusing on the sales indicators of prescription drugs can more intuitively reflect the overall hard power of pharmaceutical companies. The list data has been recognized by many medical companies and institutions and has become an important indicator for corporate report analysis and bidding procurement. This year is the 23rd time that Pharmaceutical Manager magazine of the United States launched the TOP50 list of global pharmaceutical companies. In 2019, China pharmaceutical companies were selected for the first time, and China biopharmaceuticals ranked 42nd in the world that year, ranking first among China pharmaceutical companies.
In the list of 2023, among the four pharmaceutical companies in China, China Bio-Pharmaceutical ranked 39th (40th last year), ranking on the list for the fifth consecutive year, and once again topping the list of pharmaceutical companies in China; Followed by Shanghai Pharmaceutical, ranking 41 (41 last year); Hengrui Pharma ranked 43rd (32 last year) and Unacon ranked 48th (43 last year).
The list shows that the sales of prescription drugs in China Biomedical, Shanghai Pharmaceutical, Hengrui Pharma and Unacon in 2022 were US$ 4.463 billion, US$ 4.043 billion, US$ 4.01 billion and US$ 3.334 billion respectively; In 2022, the R&D investment was $601 million, $261 million, $893 million and $511 million respectively.
Among the four pharmaceutical companies in China, three of the best-selling prescription drugs in 2022 entered the list. Among them, the highest sales volume of biopharmaceuticals in China is Anlotinib Hydrochloride Capsules (trade name "Forcovir"), the top sales volume of prescription drugs in Shanghai Medicine is Tanshinone IIA- sodium sulfonate (trade name "Nuoxinkang"), Karelizuzumab in Hengrui Pharma (trade name "Erica") and butylphthalide (trade name "Enbipu") in Unacon.
China biopharmaceuticals, which once again topped the list of pharmaceutical companies in China, gradually entered the harvest period: in 2022, 23 new clinical indications were approved, involving 17 innovative drugs, and more than 50 innovative drugs were in the clinical and marketing application stage. Since 2023, many innovative drugs, including limaprost and Eiberg Stine α (long-acting G-CSF), have been approved for marketing, and many innovative drugs, such as TQ-B3525 tablets (PI3Kδ/α double inhibitors), have been submitted for marketing. In the next three years, it is estimated that more than 10 innovative drugs will be listed, and more than 40 innovative drugs under research are expected to be listed on or before 2030.
According to the analysis of Pharmaceutical Manager, with the sales of COVID-19 products falling sharply after reaching the peak, it is foreseeable that the trend of non-epidemic treatment, market drivers, macroeconomic and geopolitical factors will once again become the focus of the industry. In the next few years, the ranking of the top 50 pharmaceutical companies may face great changes. Competition in the fields of diet drugs represented by GLP-1 (glucagon-like peptide -1) receptor agonists, RSV (respiratory syncytial virus) vaccines and drugs for Alzheimer’s disease may affect the ranking of top pharmaceutical companies in the future.
Proofread Wang Xin
关于作者